Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.73 |
| ▸ | DRD2 | P14416 | 8/20 | 0.73 |
| ▸ | DRD3 | P35462 | 8/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5288157 | 0.93 | DRD2 (0.70) | DRD4DRD2DRD3NPC1KCNH2 | |
| SCHEMBL5929468 | 0.89 | DRD2 (0.68) | DRD4DRD2DRD3KCNH2L3MBTL1 | |
| SCHEMBL9770319 | 0.89 | DRD4 (0.59) | DRD4DRD2DRD3NPC1KCNH2 | |
| SCHEMBL22894182 | 0.87 | DRD2 (0.63) | DRD4DRD2DRD3NPC1KCNH2 | |
| SCHEMBL14586644 | 0.84 | DRD2 (0.60) | DRD4DRD2DRD3NPC1KCNH2 | |
| Hydrochloric Acid SCHEMBL8055016 | 0.84 | DRD4 (0.97) | DRD4DRD2DRD3NPC1 | |
| SCHEMBL9770302 | 0.84 | ALDH3A1 (0.62) | DRD4DRD2DRD3NPC1KCNH2 | |
| SCHEMBL3805304 | 0.84 | DRD2 (0.68) | DRD4DRD2DRD3KCNH2L3MBTL1 | |
| SCHEMBL15220294 | 0.83 | DRD2 (0.58) | DRD4DRD2DRD3NPC1KCNH2 | |
| SCHEMBL10345746 | 0.82 | ALDH1A1 (0.59) | DRD4DRD2DRD3NPC1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | DRD4 4764/4885DRD2 4804/4885DRD3 4789/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | DRD4 4764/4885DRD2 4804/4885DRD3 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.